Selank and Semax nasal sprays: hype vs. actual human data

What did @kristinastout actually say?

She promoted two compounded peptide nasal sprays, Selank and Semax, claiming Selank is "really great for helping improve mood" and "helps with anxiety," while Semax is "great for mental clarity" and "helps with focus." She also made a specific pharmacokinetic argument: that nasal delivery crosses the blood-brain barrier more effectively than injection. She was careful to distinguish her products as coming from a 503A compounding pharmacy, not gray-market research peptides, and pointed viewers toward a telehealth consult at Harmony Wellness Clinic.

That framing matters. The "not for human consumption" distinction she draws is a real regulatory category, not marketing spin. But the clinical claims are doing a lot of work for compounds with a thin Western evidence base.

Does the science back this up?

Partially, and with significant caveats. Most of the evidence for both peptides comes from Russian research conducted in the 1980s through 2000s, which raises reproducibility concerns that any honest reviewer has to acknowledge.

Semax, a synthetic analog of ACTH(4-7), has shown neuroprotective and nootropic effects in animal models and small Russian clinical trials. A 2014 study by Eremin et al. published in Molecular Biology found Semax altered expression of neurotrophic and immune-related genes in rat brain tissue. Human data is sparse. For Selank, a tuftsin analog, Russian placebo-controlled trials, including work by Semenova et al. (2010) in Bulletin of Experimental Biology and Medicine, found anxiolytic effects comparable to standard benzodiazepines in generalized anxiety disorder patients, with fewer sedating side effects. That is genuinely interesting. It is not, however, FDA-reviewed evidence, and these trials were small and conducted outside standard Western regulatory frameworks.

The anxiety and mood claims for Selank have the most support. The focus and mental clarity claims for Semax are plausible given its BDNF-modulating mechanisms, but "plausible" is not the same as proven in well-controlled human trials.

What did they get wrong (or right)?

The nasal delivery argument is largely correct, and credit is due here. Both Semax and Selank were actually designed for intranasal administration specifically because the olfactory pathway provides relatively direct access to the central nervous system, bypassing systemic first-pass metabolism. Research on intranasal peptide delivery, including work by Thorne et al. (2004) in Neuroscience, confirms that olfactory transport is a viable route for CNS delivery of small peptides. Saying nasal beats injection for brain-targeted peptides is not a stretch for these specific compounds.

What she got wrong, or at least glossed over: she presented mood, anxiety, and focus benefits as established facts rather than preliminary findings. There are no large, randomized, double-blind FDA-reviewed trials for either compound in healthy adults. The Russian literature, while suggestive, cannot simply be imported as clinical confirmation. She also made no mention of side effect profiles, contraindications, or the fact that long-term safety data in humans essentially does not exist. For a nurse talking to 13,000 people, that is a meaningful omission.

What should you actually know?

If you are considering these peptides, the 503A compounding pharmacy distinction she raises is real and regulatory. A 503A pharmacy compounds for individual patients under a valid prescription, which is a different legal category than buying unlabeled vials from a research supplier. That distinction affects sterility standards, ingredient sourcing, and legal accountability. She is right to emphasize it.

That said, compounded does not mean clinically validated. These peptides are not FDA-approved drugs. They are not approved for any indication. A compounding pharmacy can legally prepare them for a prescriber, but that process does not generate the safety and efficacy data that a drug approval requires.

The anxiety signal for Selank is the most credible claim here, backed by at least some controlled trial data. The cognitive enhancement framing for Semax is the weakest, most consistent with a pattern where promising animal and small human data gets amplified into confident wellness marketing before large trials are ever run. Anyone booking a consult should go in asking specifically what evidence the clinic is using to personalize dosing, and what monitoring they provide.